Lundbeck acquires Elaiapharm

Lundbeck has revealed that it has acquired one of its former suppliers – the French firm Elaiapharm – as it strives to enchance its production and packaging facilities.

In its latest move, the firm is seeking to reduce costs in the current climate, become more flexible when it comes to its pharmaceutical division and expand its global production and capacity.

Elaiapharm has manufactured and packed Lundbeck’s pharmaceuticals as a sub-contractor for several years and will now form part of the company’s group.

Lars Bang, executive vice-president of supply operations and engineering at Lundbeck, said: “Through our many years of collaboration, we have come to know Elaiapharm as a competent and stable business and we’re pleased to complete this transaction.”

The French firm, which is currently based in Nice, deals with the processing of active pharmaceutical ingredients from chemical factories into finished tablets or vial medicines.

Last month, Lundbeck revealed that it has launched an efficiency improvement initiative that includes restructuring and rationalisation measures in order for the firm to maximise its resources for the future.